Apoptosis	O
mediated	O
by	O
HIV	B-protein
protease	I-protein
is	O
preceded	O
by	O
cleavage	O
of	O
Bcl-2	B-protein
.	O

Expression	O
of	O
the	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV	I-protein
)	I-protein
protease	I-protein
in	O
cultured	B-cell_line
cells	I-cell_line
leads	O
to	O
apoptosis	O
,	O
preceded	O
by	O
cleavage	O
of	O
bcl-2	B-protein
,	O
a	O
key	O
negative	O
regulator	O
of	O
cell	O
death	O
.	O

In	O
contrast	O
,	O
a	O
high	O
level	O
of	O
bcl-2	B-protein
protects	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
from	O
the	O
viral	B-protein
protease	I-protein
and	O
prevents	O
cell	O
death	O
following	O
HIV	O
infection	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
while	O
reducing	O
the	O
yields	O
of	O
viral	B-protein
structural	I-protein
proteins	I-protein
,	O
infectivity	O
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O

We	O
present	O
a	O
model	O
for	O
HIV	O
replication	O
in	O
which	O
the	O
viral	B-protein
protease	I-protein
depletes	O
the	O
infected	O
cells	O
of	O
bcl-2	B-protein
,	O
leading	O
to	O
oxidative	O
stress-dependent	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
a	O
cellular	B-protein
factor	I-protein
required	O
for	O
HIV	O
transcription	O
,	O
and	O
ultimately	O
to	O
cell	O
death	O
.	O

Purified	O
bcl-2	B-protein
is	O
cleaved	O
by	O
HIV	B-protein
protease	I-protein
between	O
phenylalanine	O
112	O
and	O
alanine	O
113	O
.	O

The	O
results	O
suggest	O
a	O
new	O
option	O
for	O
HIV	O
gene	O
therapy	O
;	O
bcl-2	B-protein
muteins	I-protein
that	O
have	O
noncleavable	B-protein
alterations	I-protein
surrounding	O
the	O
HIV	B-protein
protease	I-protein
cleavage	I-protein
site	I-protein
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

93	NULL
,	NULL
1pp	NULL
.	NULL

9571-9576	NULL
,	NULL
September	NULL
1996	NULL
Cell	NULL
Biology	NULL
Apoptosis	NULL
mediated	NULL
by	NULL
HIV	NULL
protease	NULL
is	NULL
preceded	NULL
by	NULL
cleavage	NULL
of	NULL
Bel-2	NULL
(	NULL
AIDS	NULL
death	NULL
PETER	NULL
R.	NULL
STRACK*	NULL
,	NULL
MICHELLE	NULL
WEST	NULL
FREY	NULL
,	NULL
CHRISTOPHER	NULL
J.	NULL
Rizzo	NULL
,	NULL
BevERrLy	NULL
CORDOVA	NULL
,	NULL
HENRY	NULL
J.	NULL
GEORGE	NULL
,	NULL
RAYMOND	NULL
MEADE	NULL
,	NULL
SIEW	NULL
PENG	NULL
Ho	NULL
,	NULL
JEANNE	NULL
CORMAN	NULL
,	NULL
RaADONNA	NULL
TRITCH	NULL
,	NULL
AND	NULL
BRUCE	NULL
D.	NULL
Korantt	NULL
Molecular	NULL
Biology	NULL
Department	NULL
,	NULL
DuPont	NULL
Merck	NULL
Pharmaceutical	NULL
Company	NULL
,	NULL
Experimental	NULL
Station	NULL
,	NULL
Building	NULL
336	NULL
,	NULL
Wilmington	NULL
,	NULL
DE	NULL
19880-0336	NULL
Communicated	NULL
by	NULL
James	NULL
E.	NULL
Darnell	NULL
,	NULL
Jr.	NULL
,	NULL
The	NULL
Rockefeller	NULL
University	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
May	NULL
20	NULL
,	NULL
1996	NULL
(	NULL
received	NULL
for	NULL
review	NULL
March	NULL
1	NULL
,	NULL
1996	NULL
)	NULL
ABSTRACT	NULL
Expression	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV	NULL
)	NULL
protease	NULL
in	NULL
cultured	NULL
cells	NULL
leads	NULL
to	NULL
apoptosis	NULL
,	NULL
preceded	NULL
by	NULL
cleavage	NULL
of	NULL
bel-2	NULL
,	NULL
a	NULL
key	NULL
negative	NULL
regulator	NULL
of	NULL
cell	NULL
death	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
a	NULL
high	NULL
level	NULL
of	NULL
bel-2	NULL
protects	NULL
cells	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
from	NULL
the	NULL
viral	NULL
protease	NULL
and	NULL
prevents	NULL
cell	NULL
death	NULL
following	NULL
HIV	NULL
infection	NULL
of	NULL
human	NULL
lymphocytes	NULL
,	NULL
while	NULL
reducing	NULL
the	NULL
yields	NULL
of	NULL
viral	NULL
structural	NULL
proteins	NULL
,	NULL
infectivity	NULL
,	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
&	NULL
.	NULL

We	NULL
present	NULL
a	NULL
model	NULL
for	NULL
HIV	NULL
replication	NULL
in	NULL
which	NULL
the	NULL
viral	NULL
protease	NULL
depletes	NULL
the	NULL
infected	NULL
cells	NULL
of	NULL
bel-2	NULL
,	NULL
leading	NULL
to	NULL
oxidative	NULL
stress-dependent	NULL
activation	NULL
of	NULL
NFKB	NULL
,	NULL
a	NULL
cellular	NULL
factor	NULL
required	NULL
for	NULL
HIV	NULL
transcription	NULL
,	NULL
and	NULL
ultimately	NULL
to	NULL
cell	NULL
death	NULL
.	NULL

Purified	NULL
bel-2	NULL
is	NULL
cleaved	NULL
by	NULL
HIV	NULL
protease	NULL
between	NULL
phenylalanine	NULL
112	NULL
and	NULL
alanine	NULL
113	NULL
.	NULL

The	NULL
results	NULL
suggest	NULL
a	NULL
new	NULL
option	NULL
for	NULL
HIV	NULL
gene	NULL
therapy	NULL
;	NULL
bel-2	NULL
muteins	NULL
that	NULL
have	NULL
non-cleavable	NULL
alterations	NULL
surrounding	NULL
the	NULL
HIV	NULL
protease	NULL
cleavage	NULL
site	NULL
.	NULL

Loss	NULL
of	NULL
immunocompetent	NULL
lymphocytes	NULL
,	NULL
as	NULL
well	NULL
as	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
is	NULL
the	NULL
hallmark	NULL
of	NULL
progressive	NULL
infection	NULL
by	NULL
HIV	NULL
.	NULL

Lymphocytes	NULL
infected	NULL
in	NULL
vitro	NULL
soon	NULL
die	NULL
by	NULL
the	NULL
process	NULL
of	NULL
apoptosis	NULL
and	NULL
cells	NULL
taken	NULL
from	NULL
HIV-infected	NULL
people	NULL
proceed	NULL
to	NULL
apoptotic	NULL
death	NULL
when	NULL
placed	NULL
in	NULL
culture	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Examination	NULL
of	NULL
biopsy	NULL
or	NULL
autopsy	NULL
material	NULL
from	NULL
HIV-infected	NULL
people	NULL
reveals	NULL
apoptosis	NULL
coincident	NULL
with	NULL
or	NULL
adjacent	NULL
to	NULL
infected	NULL
cells	NULL
(	NULL
3	NULL
)	NULL
.	NULL

There	NULL
are	NULL
reports	NULL
of	NULL
the	NULL
HIV	NULL
gene	NULL
products	NULL
tat	NULL
and	NULL
gp120	NULL
having	NULL
cytotoxic	NULL
or	NULL
apoptotic	NULL
effects	NULL
,	NULL
but	NULL
usually	NULL
a	NULL
secondary	NULL
stimulus	NULL
must	NULL
be	NULL
included	NULL
,	NULL
such	NULL
as	NULL
serum	NULL
factor	NULL
depletion	NULL
or	NULL
addition	NULL
of	NULL
cell	NULL
surface	NULL
antibodies	NULL
(	NULL
4	NULL
)	NULL
.	NULL

In	NULL
comparison	NULL
,	NULL
Krausslich	NULL
(	NULL
5	NULL
)	NULL
reported	NULL
direct	NULL
toxic	NULL
effects	NULL
following	NULL
expression	NULL
of	NULL
the	NULL
HIV	NULL
aspartic	NULL
protease	NULL
in	NULL
cultured	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
examined	NULL
HIV	NULL
protease-expressing	NULL
cells	NULL
in	NULL
greater	NULL
detail	NULL
,	NULL
and	NULL
observe	NULL
structural	NULL
changes	NULL
characteristic	NULL
of	NULL
apoptosis	NULL
,	NULL
a	NULL
typical	NULL
ladder-like	NULL
DNA	NULL
fragmentation	NULL
pattern	NULL
and	NULL
depression	NULL
of	NULL
the	NULL
signal	NULL
from	NULL
cellular	NULL
enzymatic	NULL
reporters	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

Preceding	NULL
cell	NULL
death	NULL
,	NULL
bel-2	NULL
,	NULL
a	NULL
key	NULL
negative	NULL
regulator	NULL
of	NULL
apoptosis	NULL
(	NULL
8	NULL
)	NULL
is	NULL
cleaved	NULL
by	NULL
the	NULL
viral	NULL
protease	NULL
.	NULL

We	NULL
describe	NULL
the	NULL
sites	NULL
in	NULL
bel-2	NULL
hydrolyzed	NULL
by	NULL
HIV	NULL
protease	NULL
and	NULL
show	NULL
that	NULL
a	NULL
circuit	NULL
exists	NULL
between	NULL
virus	NULL
protease-mediated	NULL
loss	NULL
of	NULL
bel-2	NULL
and	NULL
activation	NULL
of	NULL
NFkB	NULL
,	NULL
a	NULL
redox-sensitive	NULL
transcription	NULL
factor	NULL
required	NULL
for	NULL
HIV	NULL
replication	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
lymphocytes	NULL
over-producing	NULL
bel-2	NULL
,	NULL
we	NULL
report	NULL
down-regulation	NULL
of	NULL
NFKB-containing	NULL
sequences	NULL
,	NULL
specifically	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
(	NULL
TNF-a	NULL
)	NULL
,	NULL
leading	NULL
to	NULL
a	NULL
cytoprotective	NULL
and	NULL
antiviral	NULL
effect	NULL
against	NULL
HIV	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Transfection	NULL
of	NULL
Cell	NULL
Lines	NULL
.	NULL

Expression	NULL
plasmids	NULL
containing	NULL
the	NULL
human	NULL
cytomegalovirus	NULL
immediate	NULL
early	NULL
promoter	NULL
and	NULL
either	NULL
the	NULL
firefly	NULL
luciferase	NULL
,	NULL
human	NULL
be/-2	NULL
,	NULL
or	NULL
HIV	NULL
protease	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

9571	NULL
genes	NULL
were	NULL
used	NULL
for	NULL
transient	NULL
transfection	NULL
of	NULL
cells	NULL
.	NULL

Other	NULL
strong	NULL
promoters	NULL
could	NULL
be	NULL
substituted	NULL
with	NULL
no	NULL
difference	NULL
in	NULL
results	NULL
.	NULL

Plasmid	NULL
DNA	NULL
was	NULL
purified	NULL
using	NULL
cesium	NULL
chloride	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

Cells	NULL
(	NULL
10	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
purified	NULL
plasmid	NULL
DNA	NULL
using	NULL
a	NULL
Bio-Rad	NULL
Genepulser	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
/95	NULL
%	NULL
air	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
minimal	NULL
essential	NULL
medium	NULL
or	NULL
RPMI	NULL
1640	NULL
(	NULL
GIBCO	NULL
)	NULL
,	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

Assays	NULL
.	NULL

Measurement	NULL
of	NULL
cellular	NULL
oxidative	NULL
status	NULL
.	NULL

Cells	NULL
were	NULL
assayed	NULL
for	NULL
glutathione	NULL
levels	NULL
(	NULL
9	NULL
)	NULL
,	NULL
intracellular	NULL
lipid	NULL
peroxidation	NULL
(	NULL
10	NULL
)	NULL
,	NULL
binding	NULL
of	NULL
nuclear	NULL
extracts	NULL
to	NULL
a	NULL
*°P	NULL
end-labeled	NULL
oligonucleotide	NULL
specific	NULL
for	NULL
NFB	NULL
(	NULL
11	NULL
)	NULL
or	NULL
TNF	NULL
antigen	NULL
released	NULL
into	NULL
the	NULL
extracellular	NULL
medium	NULL
using	NULL
a	NULL
monoclonal	NULL
antibody	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
.	NULL

Cleavage	NULL
of	NULL
S-labeled	NULL
bel-2	NULL
.	NULL

°S-L-methionine-labeled	NULL
bel-2	NULL
was	NULL
synthesized	NULL
in	NULL
a	NULL
rabbit	NULL
reticulocyte	NULL
lysate	NULL
coupled	NULL
tran-scription/translation	NULL
system	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
and	NULL
reactions	NULL
were	NULL
terminated	NULL
with	NULL
cycloheximide	NULL
(	NULL
20	NULL
ug/ml	NULL
)	NULL
.	NULL

Canine	NULL
pancreatic	NULL
microsomal	NULL
membranes	NULL
(	NULL
four	NULL
equivalents	NULL
)	NULL
were	NULL
added	NULL
and	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

Membrane-associated	NULL
bel-2	NULL
was	NULL
recovered	NULL
by	NULL
centrifugation	NULL
in	NULL
an	NULL
Airfuge	NULL
(	NULL
Beckman	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
25	NULL
psi	NULL
.	NULL

Pellets	NULL
were	NULL
washed	NULL
(	NULL
50	NULL
mM	NULL
triethanolamine	NULL
,	NULL
pH	NULL
7.5/250	NULL
mM	NULL
sucrose/2	NULL
mM	NULL
DTT	NULL
)	NULL
,	NULL
cen-trifuged	NULL
,	NULL
and	NULL
suspended	NULL
in	NULL
40	NULL
wl	NULL
of	NULL
assay	NULL
buffer	NULL
(	NULL
12	NULL
)	NULL
.	NULL

HIV	NULL
protease	NULL
(	NULL
0.18	NULL
mg/ml	NULL
)	NULL
was	NULL
added	NULL
to	NULL
membrane-associated	NULL
bel-2	NULL
,	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
30	NULL
min	NULL
,	NULL
and	NULL
the	NULL
products	NULL
separated	NULL
by	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
in	NULL
0.1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS/PAGE	NULL
)	NULL
and	NULL
detected	NULL
by	NULL
autoradiography	NULL
.	NULL

Determination	NULL
of	NULL
HIV	NULL
protease	NULL
cleavage	NULL
sites	NULL
in	NULL
bel-2	NULL
.	NULL

Bcl-2	NULL
was	NULL
purified	NULL
from	NULL
Sf21	NULL
insect	NULL
cells	NULL
infected	NULL
with	NULL
a	NULL
baculovirus	NULL
expressing	NULL
human	NULL
bel-2	NULL
cDNA	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
lysed	NULL
by	NULL
sonication	NULL
(	NULL
3	NULL
X	NULL
20	NULL
sec	NULL
)	NULL
in	NULL
50	NULL
ml	NULL
of	NULL
lysis	NULL
buffer	NULL
{	NULL
25	NULL
mM	NULL
TrisHCl	NULL
,	NULL
pH	NULL
8.0/5	NULL
mM	NULL
EDTA/2	NULL
mM	NULL
2-mercaptoethanol/1	NULL
mM	NULL
Pefabloc	NULL
SC	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
/5	NULL
uM	NULL
leupeptin/	NULL
1.6	NULL
mM	NULL
benzamidine/0.5	NULL
wM	NULL
aprotinin	NULL
)	NULL
and	NULL
centrifuged	NULL
for	NULL
1	NULL
h	NULL
at	NULL
105,000	NULL
%	NULL
g.	NULL
The	NULL
pellet	NULL
was	NULL
washed	NULL
2	NULL
times	NULL
in	NULL
lysis	NULL
buffer	NULL
containing	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
and	NULL
1	NULL
M	NULL
NaCl	NULL
,	NULL
solubilized	NULL
in	NULL
lysis	NULL
buffer	NULL
containing	NULL
6	NULL
M	NULL
guanidineHCl	NULL
(	NULL
GdnHCl	NULL
)	NULL
using	NULL
10	NULL
strokes	NULL
of	NULL
a	NULL
Dounce	NULL
homogenizer	NULL
each	NULL
time	NULL
,	NULL
gently	NULL
stirred	NULL
overnight	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
centrifuged	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Soluble	NULL
material	NULL
was	NULL
diluted	NULL
to	NULL
2	NULL
M	NULL
GdnHCl	NULL
with	NULL
lysis	NULL
buffer	NULL
,	NULL
applied	NULL
to	NULL
a	NULL
phenyl-sepharose	NULL
high	NULL
performance	NULL
column	NULL
(	NULL
2.6	NULL
X	NULL
14	NULL
cm	NULL
,	NULL
Pharmacia	NULL
)	NULL
and	NULL
the	NULL
column	NULL
washed	NULL
with	NULL
lysis	NULL
buffer	NULL
(	NULL
100	NULL
ml	NULL
)	NULL
containing	NULL
2	NULL
M	NULL
GdnHCl	NULL
.	NULL

Bound	NULL
bel-2	NULL
was	NULL
eluted	NULL
with	NULL
200	NULL
ml	NULL
of	NULL
lysis	NULL
buffer	NULL
containing	NULL
6	NULL
M	NULL
GdnHCHI	NULL
.	NULL

Eluant	NULL
was	NULL
concentrated	NULL
to	NULL
7.0	NULL
ml	NULL
(	NULL
1.8	NULL
mg/ml	NULL
)	NULL
using	NULL
an	NULL
Amicon	NULL
stirred	NULL
cell	NULL
(	NULL
3	NULL
kDa	NULL
M	NULL
,	NULL
cutoff	NULL
)	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
.	NULL

Concentrated	NULL
material	NULL
(	NULL
100	NULL
wl	NULL
)	NULL
was	NULL
adjusted	NULL
to	NULL
20	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
acetonitrile	NULL
,	NULL
0.1	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
trifluoroacetic	NULL
acid	NULL
(	NULL
TFA	NULL
)	NULL
,	NULL
centrifuged	NULL
for	NULL
2	NULL
min	NULL
at	NULL
14,000	NULL
%	NULL
g	NULL
and	NULL
the	NULL
soluble	NULL
material	NULL
applied	NULL
to	NULL
an	NULL
HPLC-C18	NULL
(	NULL
Vydak	NULL
Abbreviations	NULL
:	NULL
TNF-a	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
;	NULL
IL-10	NULL
,	NULL
interleukin	NULL
10	NULL
.	NULL

*Present	NULL
address	NULL
:	NULL
Mitotix	NULL
,	NULL
Inc.	NULL
,	NULL
One	NULL
Kendall	NULL
Square	NULL
,	NULL
Building	NULL
600	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
02139.	NULL
tTo	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

9572	NULL
Cell	NULL
Biology	NULL
:	NULL
Strack	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

HIV	NULL
protease	NULL
produces	NULL
an	NULL
apoptotic	NULL
response	NULL
in	NULL
cultured	NULL
cells	NULL
that	NULL
can	NULL
be	NULL
prevented	NULL
by	NULL
DMP323	NULL
,	NULL
a	NULL
specific	NULL
HIV	NULL
protease	NULL
inhibitor	NULL
(	NULL
14	NULL
)	NULL
or	NULL
by	NULL
supplying	NULL
IL-10	NULL
.	NULL

(	NULL
a-c	NULL
)	NULL
Electron	NULL
microscopy	NULL
:	NULL
(	NULL
a	NULL
)	NULL
control	NULL
COS-7	NULL
cells	NULL
;	NULL
(	NULL
b	NULL
)	NULL
COS-7	NULL
cells	NULL
producing	NULL
HIV	NULL
protease	NULL
(	NULL
note	NULL
chromatin	NULL
condensation	NULL
and	NULL
formation	NULL
of	NULL
cytoplasmic	NULL
vesicles	NULL
)	NULL
;	NULL
(	NULL
c	NULL
)	NULL
human	NULL
conjunctiva	NULL
cells	NULL
expressing	NULL
HIV	NULL
protease	NULL
.	NULL

(	NULL
d	NULL
)	NULL
Scanning	NULL
microscopy	NULL
of	NULL
MT2	NULL
lymphocytes	NULL
expressing	NULL
HIV	NULL
protease	NULL
,	NULL
showing	NULL
membrane	NULL
blebbing	NULL
.	NULL

Autologous	NULL
plasmid	NULL
DNA	NULL
coding	NULL
for	NULL
an	NULL
inactive	NULL
(	NULL
asp-25	NULL
gly	NULL
)	NULL
form	NULL
of	NULL
HIV	NULL
protease	NULL
(	NULL
12	NULL
)	NULL
produced	NULL
no	NULL
visible	NULL
changes	NULL
to	NULL
the	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

(	NULL
e	NULL
)	NULL
DNA	NULL
fragmentation	NULL
in	NULL
COS-7	NULL
cells	NULL
:	NULL
lane	NULL
1	NULL
,	NULL
1-kb	NULL
DNA	NULL
ladder	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
immediately	NULL
after	NULL
transfection	NULL
with	NULL
HIV	NULL
protease	NULL
DNA	NULL
;	NULL
lanes	NULL
3-5	NULL
:	NULL
6	NULL
,	NULL
24	NULL
,	NULL
and	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
respectively	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
with	NULL
the	NULL
inactive	NULL
Cell	NULL
Biology	NULL
:	NULL
Strack	NULL
et	NULL
al	NULL
.	NULL

4.5	NULL
x	NULL
250	NULL
mm	NULL
,	NULL
Model	NULL
218TPC18	NULL
)	NULL
reverse	NULL
phase	NULL
column	NULL
.	NULL

The	NULL
HPLC-C18	NULL
column	NULL
was	NULL
washed	NULL
with	NULL
20	NULL
%	NULL
acetonitrile	NULL
in	NULL
0.1	NULL
%	NULL
TFA	NULL
,	NULL
and	NULL
bound	NULL
material	NULL
eluted	NULL
with	NULL
the	NULL
following	NULL
linear	NULL
gradients	NULL
in	NULL
0.1	NULL
%	NULL
TFA	NULL
:	NULL
20	NULL
to	NULL
65	NULL
%	NULL
acetonitrile	NULL
(	NULL
4	NULL
ml	NULL
)	NULL
,	NULL
65	NULL
to	NULL
85	NULL
%	NULL
acetonitrile	NULL
(	NULL
20	NULL
ml	NULL
)	NULL
,	NULL
85	NULL
to	NULL
100	NULL
%	NULL
acetonitrile	NULL
(	NULL
4	NULL
ml	NULL
)	NULL
.	NULL

Bound	NULL
bel-2	NULL
eluted	NULL
at	NULL
75	NULL
%	NULL
acetonitrile	NULL
,	NULL
with	NULL
recovery	NULL
of	NULL
approximately	NULL
700	NULL
ug	NULL
from	NULL
10°	NULL
cells	NULL
The	NULL
peak	NULL
fractions	NULL
containing	NULL
purified	NULL
bel-2	NULL
were	NULL
concentrated	NULL
40-fold	NULL
in	NULL
a	NULL
Speed	NULL
Vac	NULL
using	NULL
siliconized	NULL
tubes	NULL
and	NULL
adjusted	NULL
to	NULL
20	NULL
mM	NULL
Pipes	NULL
(	NULL
pH	NULL
6.1	NULL
)	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
and	NULL
125	NULL
mM	NULL
NaCl	NULL
.	NULL

Purified	NULL
bel-2	NULL
was	NULL
reacted	NULL
with	NULL
HIV	NULL
protease	NULL
for	NULL
16	NULL
h	NULL
at	NULL
23°C	NULL
,	NULL
using	NULL
a	NULL
substrate	NULL
:	NULL
enzyme	NULL
ratio	NULL
ranging	NULL
from	NULL
100:1	NULL
to	NULL
4:1	NULL
.	NULL

Amino	NULL
terminal	NULL
residues	NULL
were	NULL
determined	NULL
by	NULL
automated	NULL
Edman	NULL
degradation	NULL
in	NULL
a	NULL
Porton	NULL
PI	NULL
2090	NULL
protein	NULL
sequenater	NULL
(	NULL
Beck-man	NULL
)	NULL
.	NULL

Electrophoresis	NULL
.	NULL

Proteins	NULL
were	NULL
resolved	NULL
by	NULL
SDS/PAGE	NULL
,	NULL
and	NULL
detected	NULL
by	NULL
silver	NULL
stain	NULL
,	NULL
autoradiography	NULL
,	NULL
or	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

Proteins	NULL
for	NULL
Western	NULL
blot	NULL
analysis	NULL
were	NULL
transferred	NULL
to	NULL
Immobilon	NULL
membranes	NULL
(	NULL
Millipore	NULL
)	NULL
,	NULL
reacted	NULL
with	NULL
appropriate	NULL
primary	NULL
antibody	NULL
,	NULL
and	NULL
detected	NULL
using	NULL
a	NULL
chemiluminescent	NULL
peroxidase	NULL
substrate	NULL
(	NULL
DuPont/NEN	NULL
)	NULL
with	NULL
peroxidase-coupled	NULL
anti-primary	NULL
IgG	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

DNA	NULL
analysis	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
0.8	NULL
%	NULL
agarose	NULL
gels	NULL
and	NULL
products	NULL
were	NULL
detected	NULL
by	NULL
staining	NULL
with	NULL
0.2	NULL
ug/ml	NULL
of	NULL
ethidium	NULL
bromide	NULL
under	NULL
UV	NULL
illumination	NULL
.	NULL

In	NULL
Vivo	NULL
Activity	NULL
of	NULL
bel-2	NULL
in	NULL
Mouse	NULL
Muscle	NULL
.	NULL

Autologous	NULL
plasmids	NULL
expressing	NULL
the	NULL
HIV	NULL
protease	NULL
,	NULL
firefly	NULL
luciferase	NULL
,	NULL
or	NULL
bel-2	NULL
genes	NULL
were	NULL
constructed	NULL
and	NULL
purified	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Plasmid	NULL
DNA	NULL
samples	NULL
(	NULL
10	NULL
pg	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
phosphate	NULL
buffered	NULL
saline	NULL
,	NULL
pH	NULL
7.2	NULL
)	NULL
and	NULL
DMP323	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
were	NULL
injected	NULL
with	NULL
a	NULL
27-gauge	NULL
needle	NULL
into	NULL
quadriceps	NULL
muscles	NULL
of	NULL
Avertin-anesthetized	NULL
,	NULL
30-day-old	NULL
BALB/c	NULL
female	NULL
mice	NULL
.	NULL

DMP323	NULL
was	NULL
provided	NULL
by	NULL
P.	NULL
Lam	NULL
(	NULL
DuPont	NULL
Merck	NULL
)	NULL
.	NULL

Animals	NULL
were	NULL
sacrificed	NULL
after	NULL
48	NULL
h	NULL
,	NULL
and	NULL
the	NULL
quadriceps	NULL
muscles	NULL
removed	NULL
,	NULL
weighed	NULL
,	NULL
and	NULL
extracted	NULL
using	NULL
mechanical	NULL
homogenization	NULL
in	NULL
luciferase	NULL
assay	NULL
buffer	NULL
,	NULL
as	NULL
described	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
Dynatech	NULL
ML	NULL
1000	NULL
plate	NULL
luminometer	NULL
.	NULL

RESULTS	NULL
AND	NULL
DISCUSSION	NULL
HIV	NULL
Protease	NULL
Causes	NULL
Apoptosis	NULL
in	NULL
Cultured	NULL
Cells	NULL
.	NULL

Following	NULL
transfection	NULL
of	NULL
a	NULL
plasmid	NULL
coding	NULL
for	NULL
the	NULL
HIV	NULL
protease	NULL
,	NULL
fibroblast	NULL
,	NULL
epithelial	NULL
,	NULL
and	NULL
lymphocyte	NULL
cell	NULL
lines	NULL
die	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
death	NULL
pattern	NULL
is	NULL
apoptotic	NULL
in	NULL
appearance	NULL
with	NULL
cell	NULL
rounding	NULL
,	NULL
chromatin	NULL
condensation	NULL
,	NULL
formation	NULL
of	NULL
cytoplasmic	NULL
vesicles	NULL
,	NULL
and	NULL
blebbing	NULL
,	NULL
accompanied	NULL
by	NULL
characteristic	NULL
DNA	NULL
laddering	NULL
.	NULL

Inhibition	NULL
of	NULL
HIV	NULL
protease-mediated	NULL
apoptosis	NULL
is	NULL
accomplished	NULL
by	NULL
addition	NULL
of	NULL
the	NULL
HIV	NULL
protease	NULL
inhibitor	NULL
DMP323	NULL
(	NULL
14	NULL
)	NULL
,	NULL
or	NULL
by	NULL
treating	NULL
the	NULL
cells	NULL
with	NULL
interleukin	NULL
10	NULL
(	NULL
IL-10	NULL
)	NULL
,	NULL
stem	NULL
cell	NULL
factor	NULL
,	NULL
or	NULL
pentoxifylline	NULL
,	NULL
a	NULL
cytoprotectant	NULL
that	NULL
has	NULL
metal	NULL
chelating	NULL
and	NULL
anti-NFB	NULL
properties	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

Similar	NULL
treatments	NULL
also	NULL
suppress	NULL
replication	NULL
of	NULL
HIV	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
HIV	NULL
protease	NULL
detected	NULL
after	NULL
transfection	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
quantity	NULL
of	NULL
protease	NULL
found	NULL
in	NULL
HIV-infected	NULL
cells	NULL
,	NULL
as	NULL
estimated	NULL
from	NULL
Western	NULL
blot	NULL
analysis	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

bel-2	NULL
Is	NULL
Cleaved	NULL
by	NULL
HIV	NULL
Protease	NULL
.	NULL

We	NULL
observed	NULL
no	NULL
changes	NULL
to	NULL
most	NULL
cellular	NULL
proteins	NULL
in	NULL
the	NULL
protease-expressing	NULL
cells	NULL
when	NULL
we	NULL
employed	NULL
one	NULL
and	NULL
two-dimensional	NULL
gel	NULL
electrophoresis	NULL
and	NULL
Western	NULL
blot	NULL
analyses	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
although	NULL
there	NULL
have	NULL
been	NULL
several	NULL
reports	NULL
of	NULL
cellular	NULL
cytoskeletal	NULL
proteins	NULL
serving	NULL
as	NULL
HIV	NULL
protease	NULL
substrates	NULL
in	NULL
cell-free	NULL
experiments	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

18	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
cellular	NULL
protein	NULL
that	NULL
is	NULL
cleaved	NULL
is	NULL
bel-2	NULL
,	NULL
a	NULL
key	NULL
negative	NULL
regulator	NULL
of	NULL
apoptosis	NULL
.	NULL

When	NULL
we	NULL
examined	NULL
the	NULL
stability	NULL
of	NULL
endogenous	NULL
bel-2	NULL
in	NULL
cell-free	NULL
extracts	NULL
or	NULL
cells	NULL
exposed	NULL
to	NULL
HIV	NULL
protease	NULL
,	NULL
we	NULL
saw	NULL
a	NULL
loss	NULL
of	NULL
full-size	NULL
(	NULL
26	NULL
kDa	NULL
)	NULL
bel-2	NULL
and	NULL
the	NULL
appearance	NULL
of	NULL
proteolytic	NULL
fragments	NULL
;	NULL
the	NULL
predominant	NULL
ones	NULL
having	NULL
apparent	NULL
molecular	NULL
sizes	NULL
of	NULL
approximately	NULL
12-14	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
9573	NULL
10	NULL
2	NULL
3	NULL
4	NULL
5	NULL
nith	NULL
@	NULL
an	NULL
we	NULL
a	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
1112	NULL
1314	NULL
1518	NULL
j	NULL
.	NULL

-	NULL
6.2	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Cleavage	NULL
of	NULL
bel-2	NULL
by	NULL
HIV	NULL
protease	NULL
.	NULL

Lanes	NULL
1-4	NULL
:	NULL
Western	NULL
blot	NULL
detection	NULL
of	NULL
bel-2	NULL
cleavage	NULL
products	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
recombinant	NULL
bel-2	NULL
in	NULL
extract	NULL
of	NULL
baculovirus-infected	NULL
Sf21	NULL
insect	NULL
cells	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
Sf21	NULL
lysate	NULL
incubated	NULL
with	NULL
50	NULL
ng	NULL
of	NULL
HIV	NULL
protease	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
COS-7	NULL
cells	NULL
transfected	NULL
with	NULL
bel-2	NULL
for	NULL
24	NULL
h	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
bel-2	NULL
and	NULL
HIV	NULL
protease	NULL
cotransfected	NULL
in	NULL
COS-7	NULL
cells	NULL
(	NULL
24	NULL
h	NULL
)	NULL
.	NULL

Lane	NULL
5	NULL
,	NULL
bel-2	NULL
marker	NULL
;	NULL
silver	NULL
stain	NULL
detection	NULL
of	NULL
purified	NULL
HIV	NULL
protease	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
purified	NULL
bel-2	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
bel-2	NULL
and	NULL
HIV	NULL
protease	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
incubated	NULL
in	NULL
assay	NULL
buffer	NULL
at	NULL
37°C	NULL
for	NULL
4	NULL
h.	NULL
Efficient	NULL
recovery	NULL
of	NULL
recombinant	NULL
bel-2	NULL
from	NULL
baculovirus-infected	NULL
Sf21	NULL
cells	NULL
was	NULL
dependent	NULL
on	NULL
exposure	NULL
of	NULL
the	NULL
protein	NULL
to	NULL
6	NULL
M	NULL
GdnHCl	NULL
.	NULL

As	NULL
a	NULL
control	NULL
for	NULL
possible	NULL
misfolding	NULL
of	NULL
the	NULL
bel-2	NULL
used	NULL
in	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
,	NULL
microsome	NULL
bound	NULL
*5S-Met-bcl-2	NULL
was	NULL
cleaved	NULL
by	NULL
HIV	NULL
protease	NULL
.	NULL

Lane	NULL
9	NULL
,	NULL
°S-Met-bcl-2	NULL
;	NULL
lane	NULL
10	NULL
,	NULL
°S-Met-bet-2	NULL
plus	NULL
HIV	NULL
protease	NULL
.	NULL

Lanes	NULL
11-15	NULL
,	NULL
human	NULL
MT-2	NULL
lymphocytes	NULL
infected	NULL
with	NULL
HIV	NULL
,	NULL
strain	NULL
Rf	NULL
(	NULL
0.5	NULL
infectious	NULL
unit	NULL
per	NULL
cell	NULL
)	NULL
.	NULL

Bcl-2	NULL
levels	NULL
were	NULL
detected	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Lane	NULL
11	NULL
,	NULL
uninfected	NULL
cells	NULL
.	NULL

Lanes	NULL
12-15	NULL
;	NULL
6	NULL
,	NULL
17	NULL
,	NULL
24	NULL
,	NULL
48	NULL
h	NULL
post-infection	NULL
,	NULL
respectively	NULL
.	NULL

Lane	NULL
16	NULL
,	NULL
bel-2	NULL
marker	NULL
.	NULL

Lanes	NULL
17	NULL
and	NULL
18	NULL
compare	NULL
the	NULL
total	NULL
proteins	NULL
in	NULL
COS-7	NULL
cells	NULL
without	NULL
and	NULL
with	NULL
expression	NULL
of	NULL
HIV	NULL
protease	NULL
.	NULL

No	NULL
gross	NULL
differences	NULL
were	NULL
observed	NULL
using	NULL
one-	NULL
or	NULL
two-dimensional	NULL
gels	NULL
,	NULL
or	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
antibodies	NULL
against	NULL
a	NULL
variety	NULL
of	NULL
proteins	NULL
involved	NULL
in	NULL
DNA	NULL
repair	NULL
,	NULL
the	NULL
cytoskeleton	NULL
,	NULL
or	NULL
cellular	NULL
enzymes	NULL
.	NULL

Amino	NULL
acids	NULL
identified	NULL
in	NULL
sequence	NULL
after	NULL
hydrolysis	NULL
of	NULL
bei-2	NULL
by	NULL
HIV	NULL
protease	NULL
are	NULL
:	NULL
alanine	NULL
,	NULL
85	NULL
pmol	NULL
;	NULL
glutamate	NULL
,	NULL
100	NULL
pmol	NULL
;	NULL
methionine	NULL
,	NULL
72	NULL
pmol	NULL
;	NULL
serine	NULL
,	NULL
20.5	NULL
pmol	NULL
;	NULL
serine	NULL
,	NULL
2	NULL
pmol	NULL
;	NULL
glutamine	NULL
,	NULL
48.2	NULL
pmol	NULL
;	NULL
and	NULL
leucine	NULL
,	NULL
38.6	NULL
pmol	NULL
,	NULL
consistent	NULL
with	NULL
cleavage	NULL
between	NULL
phenylalanine	NULL
112	NULL
and	NULL
alanine	NULL
113	NULL
.	NULL

Also	NULL
detected	NULL
were	NULL
minor	NULL
cleavages	NULL
between	NULL
amino	NULL
acids	NULL
15	NULL
and	NULL
16	NULL
,	NULL
27	NULL
and	NULL
28	NULL
,	NULL
and	NULL
97	NULL
and	NULL
98.	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
1-5	NULL
)	NULL
.	NULL

Purified	NULL
bel-2	NULL
and	NULL
bel-2	NULL
translated	NULL
in	NULL
reticulocyte	NULL
lysates	NULL
,	NULL
after	NULL
exposure	NULL
to	NULL
HIV	NULL
protease	NULL
,	NULL
were	NULL
cleaved	NULL
into	NULL
similar	NULL
12-14-kDa	NULL
products	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
6-10	NULL
)	NULL
.	NULL

Also	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
11-15	NULL
,	NULL
is	NULL
the	NULL
time-dependent	NULL
loss	NULL
of	NULL
bel-2	NULL
,	NULL
which	NULL
occurs	NULL
in	NULL
lymphocytes	NULL
after	NULL
infection	NULL
with	NULL
HIV	NULL
(	NULL
19	NULL
)	NULL
,	NULL
although	NULL
discrete	NULL
cleavage	NULL
products	NULL
were	NULL
not	NULL
consistently	NULL
observed	NULL
.	NULL

In	NULL
comparison	NULL
,	NULL
in	NULL
cells	NULL
overproducing	NULL
HIV	NULL
protease	NULL
,	NULL
there	NULL
was	NULL
no	NULL
detectable	NULL
change	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
cellular	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
17	NULL
and	NULL
18	NULL
)	NULL
.	NULL

Acute	NULL
loss	NULL
of	NULL
bel-2	NULL
by	NULL
proteolysis	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
associated	NULL
with	NULL
apoptosis	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Gradually	NULL
reducing	NULL
the	NULL
intracellular	NULL
level	NULL
of	NULL
bel-2	NULL
message	NULL
with	NULL
antisense	NULL
technology	NULL
leads	NULL
to	NULL
onset	NULL
of	NULL
apoptosis	NULL
,	NULL
with	NULL
a	NULL
24-48	NULL
h	NULL
lag	NULL
,	NULL
as	NULL
the	NULL
endogenous	NULL
bel-2	NULL
protein	NULL
level	NULL
slowly	NULL
declines	NULL
(	NULL
20	NULL
)	NULL
.	NULL

In	NULL
transgenic	NULL
mice	NULL
in	NULL
which	NULL
the	NULL
bel-2	NULL
gene	NULL
is	NULL
interrupted	NULL
,	NULL
the	NULL
surviving	NULL
progeny	NULL
progressively	NULL
lose	NULL
their	NULL
lymphocytes	NULL
within	NULL
4	NULL
weeks	NULL
after	NULL
birth	NULL
(	NULL
21	NULL
)	NULL
.	NULL

With	NULL
all	NULL
cell	NULL
lines	NULL
(	NULL
asp-25	NULL
gly	NULL
)	NULL
HIV	NULL
protease	NULL
mutant	NULL
DNA	NULL
.	NULL

(	NULL
£-	NULL
)	NULL
Phase	NULL
microscopy	NULL
of	NULL
human	NULL
293	NULL
kidney	NULL
cells	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
with	NULL
(	NULL
f	NULL
)	NULL
no	NULL
DNA	NULL
,	NULL
(	NULL
g	NULL
)	NULL
HIV	NULL
protease	NULL
DNA	NULL
,	NULL
(	NULL
h	NULL
)	NULL
HIV	NULL
protease	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
protease	NULL
inhibitor	NULL
DMP323	NULL
(	NULL
100	NULL
ng/m1	NULL
)	NULL
,	NULL
(	NULL
?	NULL
)	NULL

HIV	NULL
protease	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
human	NULL
IL-10	NULL
(	NULL
40	NULL
ng/ml	NULL
,	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
.	NULL

9574	NULL
Cell	NULL
Biology	NULL
:	NULL
Strack	NULL
et	NULL
al	NULL
.	NULL

in	NULL
which	NULL
bei-2	NULL
cleavage	NULL
mediated	NULL
by	NULL
HIV	NULL
protease	NULL
induced	NULL
apoptosis	NULL
,	NULL
we	NULL
found	NULL
in	NULL
parallel	NULL
experiments	NULL
that	NULL
antisense	NULL
to	NULL
bel-2	NULL
also	NULL
caused	NULL
death	NULL
,	NULL
although	NULL
the	NULL
initial	NULL
apoptotic	NULL
features	NULL
were	NULL
delayed	NULL
by	NULL
12-24	NULL
h.	NULL
Expression	NULL
of	NULL
HIV	NULL
Protease	NULL
and	NULL
Loss	NULL
of	NULL
bel-2	NULL
Leads	NULL
to	NULL
Oxidative	NULL
Stress	NULL
and	NULL
NFB	NULL
Activation	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
cytoprotection	NULL
by	NULL
bel-2	NULL
is	NULL
not	NULL
clear	NULL
,	NULL
but	NULL
may	NULL
involve	NULL
suppression	NULL
of	NULL
cellular	NULL
production	NULL
of	NULL
reactive	NULL
oxygen	NULL
species	NULL
or	NULL
protection	NULL
from	NULL
such	NULL
molecules	NULL
(	NULL
8	NULL
,	NULL
22	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
transcription	NULL
of	NULL
HIV	NULL
is	NULL
induced	NULL
by	NULL
reactive	NULL
oxygen	NULL
species	NULL
(	NULL
11	NULL
,	NULL
23	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
tested	NULL
if	NULL
the	NULL
expression	NULL
of	NULL
HIV	NULL
protease	NULL
affects	NULL
intracellular	NULL
oxidative	NULL
status	NULL
.	NULL

Following	NULL
protease	NULL
expression	NULL
,	NULL
the	NULL
intracellular	NULL
concentration	NULL
of	NULL
glutathione	NULL
is	NULL
decreased	NULL
,	NULL
the	NULL
level	NULL
of	NULL
lipid	NULL
peroxidation	NULL
increased	NULL
,	NULL
the	NULL
DNA	NULL
binding	NULL
property	NULL
of	NULL
NFB	NULL
activated	NULL
and	NULL
TNF	NULL
increased	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

These	NULL
effects	NULL
,	NULL
which	NULL
can	NULL
be	NULL
partially	NULL
mimicked	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
bel-2	NULL
antisense	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
are	NULL
each	NULL
known	NULL
to	NULL
potentiate	NULL
HIV	NULL
transcription	NULL
,	NULL
and	NULL
have	NULL
been	NULL
observed	NULL
in	NULL
clinical	NULL
AIDS	NULL
(	NULL
11	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Although	NULL
we	NULL
can	NULL
not	NULL
absolutely	NULL
prove	NULL
cause	NULL
and	NULL
effect	NULL
,	NULL
the	NULL
cleavage	NULL
and	NULL
depletion	NULL
of	NULL
bel-2	NULL
by	NULL
HIV	NULL
protease	NULL
is	NULL
consistent	NULL
with	NULL
loss	NULL
of	NULL
its	NULL
claimed	NULL
antioxidant	NULL
function	NULL
.	NULL

Protective	NULL
Effect	NULL
of	NULL
bel-2	NULL
Against	NULL
HIV	NULL
Protease	NULL
Toxicity	NULL
.	NULL

The	NULL
anti-apoptosis	NULL
protein	NULL
of	NULL
adenovirus	NULL
,	NULL
Elb-19k	NULL
,	NULL
protects	NULL
Jurkat	NULL
T	NULL
cells	NULL
against	NULL
the	NULL
cytopathic	NULL
effect	NULL
of	NULL
HIV	NULL
(	NULL
24	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
bel-2	NULL
to	NULL
protect	NULL
cells	NULL
from	NULL
HIV	NULL
and	NULL
the	NULL
viral	NULL
protease	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
there	NULL
is	NULL
effective	NULL
protection	NULL
from	NULL
the	NULL
protease	NULL
if	NULL
a	NULL
plasmid	NULL
expressing	NULL
bel-2	NULL
is	NULL
present	NULL
in	NULL
the	NULL
cells	NULL
.	NULL

In	NULL
lymphocytes	NULL
,	NULL
loss	NULL
of	NULL
a	NULL
luciferase	NULL
reporter	NULL
signal	NULL
caused	NULL
by	NULL
coexpression	NULL
of	NULL
HIV	NULL
protease	NULL
is	NULL
prevented	NULL
if	NULL
bel-2	NULL
is	NULL
simultaneously	NULL
overexpressed	NULL
.	NULL

Similarly	NULL
,	NULL
lymphocytes	NULL
expressing	NULL
bel-2	NULL
do	NULL
not	NULL
become	NULL
apoptotic	NULL
when	NULL
infected	NULL
by	NULL
HIV	NULL
,	NULL
and	NULL
in	NULL
contrast	NULL
to	NULL
earlier	NULL
results	NULL
with	NULL
the	NULL
adenovirus	NULL
protein	NULL
Elb-19k	NULL
(	NULL
24	NULL
)	NULL
,	NULL
HIV	NULL
infectivity	NULL
titers	NULL
are	NULL
reduced	NULL
by	NULL
up	NULL
to	NULL
90	NULL
%	NULL
,	NULL
as	NULL
are	NULL
the	NULL
levels	NULL
of	NULL
viral	NULL
p24	NULL
core	NULL
and	NULL
gp120	NULL
envelope	NULL
proteins	NULL
,	NULL
the	NULL
number	NULL
of	NULL
syncytia	NULL
,	NULL
and	NULL
the	NULL
quantity	NULL
of	NULL
TNF	NULL
released	NULL
into	NULL
the	NULL
medium	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

These	NULL
results	NULL
provide	NULL
additional	NULL
evidence	NULL
that	NULL
above	NULL
a	NULL
threshold	NULL
level	NULL
of	NULL
bel-2	NULL
,	NULL
transcription	NULL
of	NULL
NFKB-activated	NULL
promoters	NULL
,	NULL
such	NULL
as	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
,	NULL
TNF	NULL
and	NULL
p53	NULL
(	NULL
11	NULL
,	NULL
16	NULL
,	NULL
23	NULL
)	NULL
are	NULL
suppressed	NULL
.	NULL

Bel-2	NULL
was	NULL
reported	NULL
to	NULL
protect	NULL
cultured	NULL
mammalian	NULL
cells	NULL
against	NULL
the	NULL
cytopathic	NULL
effects	NULL
of	NULL
influenza	NULL
virus	NULL
(	NULL
25	NULL
)	NULL
and	NULL
sindbis	NULL
virus	NULL
(	NULL
26	NULL
)	NULL
,	NULL
possibly	NULL
by	NULL
inhibiting	NULL
NFKB	NULL
activation	NULL
(	NULL
27	NULL
)	NULL
.	NULL

The	NULL
experiments	NULL
so	NULL
far	NULL
describe	NULL
results	NULL
only	NULL
in	NULL
cultured	NULL
cells	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
bel-2	NULL
expression	NULL
is	NULL
protective	NULL
in	NULL
vivo	NULL
,	NULL
we	NULL
Table	NULL
1	NULL
.	NULL

Effect	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
HIV	NULL
protease	NULL
or	NULL
bel-2	NULL
antisense	NULL
on	NULL
NFxB	NULL
activation-related	NULL
events	NULL
in	NULL
COS-7	NULL
cells	NULL
bel-2	NULL
Assay	NULL
Control	NULL
HIV	NULL
protease	NULL
_	NULL
antisense	NULL
Glutathione	NULL
level	NULL
(	NULL
nmol/10	NULL
``	NULL
cells	NULL
)	NULL
81.0	NULL
+	NULL
2.0	NULL
5.0	NULL
+	NULL
0.2	NULL
ND	NULL
Lipid	NULL
peroxidation	NULL
(	NULL
nmol/10	NULL
``	NULL
cells	NULL
)	NULL
7.0	NULL
+	NULL
1.0	NULL
17.0	NULL
*	NULL
1.0	NULL
25.0	NULL
+	NULL
2.0	NULL
Relative	NULL
NFB	NULL
DNA	NULL
binding	NULL
1.0	NULL
5.5	NULL
+	NULL
0.6	NULL
3.5	NULL
+	NULL
0.4	NULL
TNF	NULL
released	NULL
(	NULL
ng/ml	NULL
)	NULL
<	NULL
1.0	NULL
11.0	NULL
+	NULL
0.1	NULL
8.0	NULL
+	NULL
0.7	NULL
COS-7	NULL
cells	NULL
were	NULL
electroporated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
purified	NULL
plasmid	NULL
DNA	NULL
coding	NULL
either	NULL
for	NULL
luciferase	NULL
(	NULL
Control	NULL
)	NULL
,	NULL
HIV	NULL
protease	NULL
,	NULL
or	NULL
bel-2	NULL
antisense	NULL
RNA	NULL
.	NULL

After	NULL
17	NULL
h	NULL
of	NULL
incubation	NULL
at	NULL
37°C	NULL
,	NULL
cells	NULL
were	NULL
assayed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

For	NULL
assay	NULL
of	NULL
NFKB-binding	NULL
activity	NULL
,	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
lysed	NULL
according	NULL
to	NULL
Schreck	NULL
et	NULL
al	NULL
.	NULL

(	NULL
11	NULL
)	NULL
and	NULL
cytoplasm	NULL
or	NULL
salt-extracted	NULL
nuclear	NULL
proteins	NULL
were	NULL
reacted	NULL
for	NULL
60	NULL
min	NULL
at	NULL
25°C	NULL
with	NULL
a	NULL
P-labeled	NULL
oligonucleotide	NULL
pair	NULL
;	NULL
5'-AGT	NULL
TGA	NULL
GGG	NULL
GAC	NULL
TTT	NULL
CCC	NULL
AGG	NULL
C	NULL
3'-TCA	NULL
ACT	NULL
CCC	NULL
CTG	NULL
AAA	NULL
GGG	NULL
TCC	NULL
G	NULL
specific	NULL
for	NULL
NFB	NULL
(	NULL
specific	NULL
activity	NULL
2.3	NULL
X	NULL
10°	NULL
cpm/pmol	NULL
)	NULL
.	NULL

The	NULL
complexes	NULL
were	NULL
then	NULL
electrophoretically	NULL
separated	NULL
on	NULL
a	NULL
native	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
,	NULL
and	NULL
the	NULL
dried	NULL
gel	NULL
fluorographed	NULL
using	NULL
Kodak	NULL
XAR	NULL
film	NULL
.	NULL

The	NULL
film	NULL
was	NULL
then	NULL
scanned	NULL
with	NULL
a	NULL
recording	NULL
densitometer	NULL
and	NULL
areas	NULL
under	NULL
the	NULL
peaks	NULL
determined	NULL
.	NULL

ND	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
mean	NULL
+	NULL
SEM	NULL
of	NULL
three	NULL
determinations	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
injected	NULL
plasmids	NULL
for	NULL
luciferase	NULL
and	NULL
the	NULL
HIV	NULL
protease	NULL
into	NULL
the	NULL
quadriceps	NULL
muscles	NULL
of	NULL
mice	NULL
.	NULL

The	NULL
animals	NULL
were	NULL
sacrificed	NULL
48	NULL
h	NULL
later	NULL
and	NULL
the	NULL
quadriceps	NULL
muscles	NULL
removed	NULL
.	NULL

Muscle	NULL
homoge-	NULL
are	NULL
ae	NULL
.	NULL

area	NULL
A	NULL
'\§	NULL
’	NULL
1	NULL
``	NULL
‘	NULL
03	NULL
>	NULL
@	NULL
-	NULL
\in	NULL
w	NULL
Ale	NULL
4	NULL
-	NULL
ipr	NULL
afa	NULL
ta	NULL
s*	NULL
.	NULL

~s	NULL
nF	NULL
ela	NULL
as	NULL
d	NULL
Luc	NULL
+	NULL
HIV-Pr	NULL
Luc	NULL
+	NULL
HIV-Pr	NULL
+	NULL
bel-2	NULL
DNA	NULL
fragmentation	NULL
HIV	NULL
infectivity	NULL
HIV	NULL
p24	NULL
Syncytia	NULL
gp120	NULL
TNF	NULL
release	NULL
T	NULL
¥	NULL
0	NULL
25	NULL
SO	NULL
75	NULL
100	NULL
Fig	NULL
.	NULL

3.	NULL
bel-2	NULL
protects	NULL
cells	NULL
from	NULL
HIV	NULL
protease-mediated	NULL
cytotox-icity	NULL
.	NULL

Phase	NULL
microscopy	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
into	NULL
COS-7	NULL
cells	NULL
of	NULL
(	NULL
a	NULL
)	NULL
plasmid	NULL
DNA	NULL
control	NULL
,	NULL
(	NULL
b	NULL
)	NULL
plasmid	NULL
coding	NULL
for	NULL
HIV	NULL
protease	NULL
,	NULL
(	NULL
c	NULL
)	NULL
plasmids	NULL
coding	NULL
for	NULL
HIV	NULL
protease	NULL
and	NULL
bel-2	NULL
.	NULL

(	NULL
d	NULL
)	NULL
Bel-2	NULL
protects	NULL
human	NULL
MT-2	NULL
lymphocytes	NULL
from	NULL
HIV	NULL
protease	NULL
cytotoxicity	NULL
and	NULL
reduces	NULL
yields	NULL
of	NULL
HIV	NULL
components	NULL
and	NULL
TNF	NULL
.	NULL

Firefly	NULL
luciferase	NULL
(	NULL
luc	NULL
)	NULL
was	NULL
expressed	NULL
alone	NULL
(	NULL
control	NULL
=	NULL
100	NULL
%	NULL
,	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
with	NULL
HIV	NULL
protease	NULL
(	NULL
top	NULL
bar	NULL
)	NULL
,	NULL
or	NULL
with	NULL
HIV	NULL
protease	NULL
and	NULL
bei-2	NULL
(	NULL
second	NULL
bar	NULL
)	NULL
.	NULL

Compared	NULL
with	NULL
luciferase	NULL
control	NULL
,	NULL
at	NULL
24	NULL
h	NULL
HIV	NULL
protease	NULL
reduced	NULL
the	NULL
yield	NULL
of	NULL
luciferase	NULL
activity	NULL
to	NULL
approximately	NULL
25	NULL
%	NULL
,	NULL
whereas	NULL
bel-2	NULL
protected	NULL
the	NULL
cells	NULL
so	NULL
that	NULL
more	NULL
than	NULL
75	NULL
%	NULL
of	NULL
control	NULL
luciferase	NULL
activity	NULL
was	NULL
recovered	NULL
.	NULL

For	NULL
plotting	NULL
the	NULL
lower	NULL
six	NULL
bars	NULL
,	NULL
determinations	NULL
were	NULL
made	NULL
with	NULL
HIV-infected	NULL
lymphocytes	NULL
overproducing	NULL
bel-2	NULL
.	NULL

These	NULL
were	NULL
compared	NULL
with	NULL
unshown	NULL
controls	NULL
(	NULL
=100	NULL
%	NULL
)	NULL
representing	NULL
infected	NULL
cells	NULL
with	NULL
no	NULL
exogenous	NULL
bel-2	NULL
present	NULL
.	NULL

MT	NULL
-2	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HIV-1	NULL
virus	NULL
,	NULL
strain	NULL
Rf	NULL
(	NULL
shown	NULL
)	NULL
or	NULL
HXB2	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
0.5-1	NULL
infectious	NULL
unit	NULL
per	NULL
cell	NULL
.	NULL

Levels	NULL
of	NULL
p24	NULL
,	NULL
gp120	NULL
,	NULL
and	NULL
TNF	NULL
were	NULL
measured	NULL
by	NULL
standard	NULL
immunoassays	NULL
.	NULL

HIV	NULL
infectivity	NULL
was	NULL
determined	NULL
using	NULL
a	NULL
plaque	NULL
assay	NULL
and	NULL
syncytia	NULL
counted	NULL
among	NULL
10°	NULL
cells	NULL
using	NULL
a	NULL
phase	NULL
contrast	NULL
microscope	NULL
.	NULL

DNA	NULL
degradation	NULL
was	NULL
assayed	NULL
as	NULL
described	NULL
.	NULL

Cell	NULL
Biology	NULL
:	NULL
Strack	NULL
et	NULL
al	NULL
.	NULL

Table	NULL
2	NULL
.	NULL

In	NULL
vivo	NULL
protective	NULL
effect	NULL
of	NULL
bel-2	NULL
versus	NULL
HIV	NULL
protease	NULL
Luciferase	NULL
activity	NULL
,	NULL
Sample	NULL
light	NULL
units/mg	NULL
protein	NULL
Control	NULL
mouse	NULL
quadriceps	NULL
977	NULL
+	NULL
-	NULL
38	NULL
Luciferase	NULL
plasmid	NULL
40,120	NULL
+	NULL
3,444	NULL
Luciferase	NULL
and	NULL
protease	NULL
plasmids	NULL
4,571	NULL
=	NULL
671	NULL
37,858	NULL
+	NULL
5218	NULL
31,687	NULL
+	NULL
3,914	NULL
Luciferase	NULL
and	NULL
protease	NULL
plasmids	NULL
and	NULL
DMP323	NULL
Luciferase	NULL
and	NULL
protease	NULL
and	NULL
bel-2	NULL
plasmids	NULL
nates	NULL
were	NULL
prepared	NULL
and	NULL
luciferase	NULL
assays	NULL
showed	NULL
that	NULL
the	NULL
HIV	NULL
protease	NULL
reduces	NULL
the	NULL
yield	NULL
of	NULL
luciferase	NULL
activity	NULL
to	NULL
almost	NULL
background	NULL
levels	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
cointroduction	NULL
of	NULL
the	NULL
bel-2	NULL
expression	NULL
plasmid	NULL
protects	NULL
the	NULL
luciferase	NULL
signal	NULL
by	NULL
up	NULL
to	NULL
75	NULL
%	NULL
,	NULL
as	NULL
does	NULL
the	NULL
synthetic	NULL
HIV	NULL
protease	NULL
inhibitor	NULL
DMP323	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
bel-2	NULL
is	NULL
able	NULL
to	NULL
protect	NULL
cells	NULL
in	NULL
vivo	NULL
against	NULL
the	NULL
viral	NULL
protease	NULL
.	NULL

Determination	NULL
of	NULL
Sites	NULL
in	NULL
bel-2	NULL
Cleaved	NULL
by	NULL
HIV	NULL
Protease	NULL
.	NULL

Inhibitors	NULL
of	NULL
the	NULL
HIV	NULL
protease	NULL
were	NULL
able	NULL
to	NULL
block	NULL
cytotoxicity	NULL
of	NULL
the	NULL
enzyme	NULL
as	NULL
well	NULL
as	NULL
virus-induced	NULL
apoptosis	NULL
(	NULL
refs	NULL
.	NULL

5	NULL
and	NULL
14	NULL
,	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
HIV	NULL
protease	NULL
self-processing	NULL
and	NULL
cleavage	NULL
of	NULL
HIV	NULL
core	NULL
proteins	NULL
were	NULL
not	NULL
inhibited	NULL
in	NULL
bel-2-expressing	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
HIV	NULL
protease	NULL
action	NULL
per	NULL
se	NULL
is	NULL
not	NULL
directly	NULL
lethal	NULL
.	NULL

Instead	NULL
,	NULL
the	NULL
cells	NULL
must	NULL
be	NULL
responding	NULL
to	NULL
the	NULL
loss	NULL
of	NULL
bei-2	NULL
to	NULL
enter	NULL
the	NULL
apoptotic	NULL
pathway	NULL
.	NULL

Therefore	NULL
,	NULL
a	NULL
novel	NULL
cytoprotective	NULL
approach	NULL
could	NULL
result	NULL
from	NULL
installing	NULL
a	NULL
modified	NULL
gene	NULL
in	NULL
cells	NULL
coding	NULL
for	NULL
a	NULL
bel-2	NULL
mutein	NULL
that	NULL
was	NULL
less	NULL
susceptible	NULL
to	NULL
cleavage	NULL
by	NULL
HIV	NULL
protease	NULL
.	NULL

Before	NULL
initiating	NULL
such	NULL
an	NULL
approach	NULL
,	NULL
it	NULL
was	NULL
necessary	NULL
to	NULL
determine	NULL
the	NULL
site	NULL
(	NULL
s	NULL
)	NULL
in	NULL
bel-2	NULL
cleaved	NULL
by	NULL
HIV	NULL
protease	NULL
.	NULL

Purified	NULL
bel-2	NULL
was	NULL
reacted	NULL
with	NULL
homogeneous	NULL
HIV	NULL
protease	NULL
and	NULL
newly	NULL
generated	NULL
amino-termini	NULL
determined	NULL
by	NULL
automated	NULL
sequence	NULL
analysis	NULL
.	NULL

Results	NULL
are	NULL
summarized	NULL
in	NULL
the	NULL
Fig	NULL
.	NULL

2	NULL
legend	NULL
.	NULL

The	NULL
primary	NULL
cleavage	NULL
event	NULL
occurs	NULL
between	NULL
phenylalanine	NULL
112	NULL
and	NULL
alanine	NULL
113	NULL
,	NULL
and	NULL
the	NULL
sequence	NULL
of	NULL
amino	NULL
acids	NULL
(	NULL
RDFAEM	NULL
)	NULL
surrounding	NULL
the	NULL
cleavage	NULL
site	NULL
comprise	NULL
a	NULL
high-affinity	NULL
HIV	NULL
protease	NULL
target	NULL
(	NULL
28	NULL
)	NULL
.	NULL

The	NULL
cleavage	NULL
products	NULL
are	NULL
predicted	NULL
to	NULL
be	NULL
a	NULL
12-kDa	NULL
amino-	NULL
and	NULL
a	NULL
14-kDa	NULL
carboxy-	NULL
terminus	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

The	NULL
phenylalanine	NULL
at	NULL
position	NULL
112	NULL
is	NULL
conserved	NULL
for	NULL
bei-2	NULL
homologues	NULL
throughout	NULL
evolution	NULL
,	NULL
including	NULL
the	NULL
nematode	NULL
Caenorhabditis	NULL
elegans	NULL
(	NULL
8	NULL
)	NULL
,	NULL
and	NULL
a	NULL
recent	NULL
mutagenesis	NULL
study	NULL
assigned	NULL
a	NULL
functional	NULL
role	NULL
to	NULL
human	NULL
bel-2	NULL
amino	NULL
acids	NULL
108-114	NULL
in	NULL
preventing	NULL
apoptosis	NULL
(	NULL
29	NULL
)	NULL
.	NULL

A	NULL
protein	NULL
in	NULL
the	NULL
extended	NULL
bel-2	NULL
family	NULL
lacking	NULL
phenylalanine	NULL
in	NULL
the	NULL
homologous	NULL
position	NULL
is	NULL
bax	NULL
,	NULL
a	NULL
positive	NULL
regulator	NULL
of	NULL
apoptosis	NULL
that	NULL
dimerizes	NULL
with	NULL
bel-2	NULL
(	NULL
8	NULL
)	NULL
,	NULL
and	NULL
bax	NULL
is	NULL
not	NULL
cleaved	NULL
in	NULL
HIV	NULL
protease-expressing	NULL
or	NULL
HIV-infected	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
ratio	NULL
of	NULL
bel-2	NULL
to	NULL
bax	NULL
following	NULL
HIV	NULL
infection	NULL
thus	NULL
shifts	NULL
to	NULL
bax	NULL
excess	NULL
,	NULL
cell	NULL
death	NULL
by	NULL
apoptosis	NULL
should	NULL
be	NULL
the	NULL
expected	NULL
result	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
a	NULL
tactic	NULL
that	NULL
HIV	NULL
uses	NULL
to	NULL
upregulate	NULL
its	NULL
transcription	NULL
,	NULL
namely	NULL
proteolytic	NULL
attack	NULL
on	NULL
bel-2	NULL
,	NULL
has	NULL
the	NULL
consequence	NULL
of	NULL
being	NULL
cytocidal	NULL
.	NULL

This	NULL
is	NULL
different	NULL
from	NULL
many	NULL
other	NULL
viruses	NULL
,	NULL
which	NULL
often	NULL
code	NULL
for	NULL
proteins	NULL
that	NULL
prevent	NULL
apoptosis	NULL
and	NULL
keep	NULL
the	NULL
captured	NULL
cellular	NULL
apparatus	NULL
functioning	NULL
as	NULL
long	NULL
as	NULL
possible	NULL
(	NULL
24	NULL
)	NULL
.	NULL

HIV	NULL
may	NULL
have	NULL
evolved	NULL
a	NULL
unique	NULL
strategy	NULL
based	NULL
on	NULL
apoptosis	NULL
;	NULL
the	NULL
corpses	NULL
of	NULL
post-apoptotic	NULL
HIV-infected	NULL
lymphocytes	NULL
are	NULL
proposed	NULL
to	NULL
be	NULL
engulfed	NULL
by	NULL
monocytes	NULL
,	NULL
which	NULL
then	NULL
become	NULL
chronically	NULL
infected	NULL
by	NULL
the	NULL
ingested	NULL
proviral	NULL
DNA	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Monocytes/macrophages	NULL
are	NULL
thought	NULL
to	NULL
serve	NULL
as	NULL
important	NULL
reservoirs	NULL
and	NULL
transporters	NULL
of	NULL
the	NULL
HIV	NULL
provirus	NULL
to	NULL
distant	NULL
organs	NULL
of	NULL
the	NULL
host	NULL
.	NULL

Because	NULL
the	NULL
viral	NULL
protease	NULL
is	NULL
central	NULL
to	NULL
this	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
,	NULL
inhibition	NULL
of	NULL
virus	NULL
maturation	NULL
by	NULL
protease	NULL
inhibitors	NULL
would	NULL
seem	NULL
to	NULL
provide	NULL
the	NULL
additional	NULL
benefits	NULL
of	NULL
minimizing	NULL
cell	NULL
loss	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
,	NULL
reducing	NULL
transcription	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
,	NULL
and	NULL
preventing	NULL
activation	NULL
of	NULL
cellular	NULL
genes	NULL
that	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
pathology	NULL
of	NULL
AIDS	NULL
.	NULL

A	NULL
new	NULL
approach	NULL
,	NULL
coming	NULL
from	NULL
the	NULL
results	NULL
given	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
is	NULL
to	NULL
modify	NULL
bel-2	NULL
to	NULL
decrease	NULL
its	NULL
susceptibility	NULL
to	NULL
the	NULL
action	NULL
of	NULL
HIV	NULL
protease	NULL
,	NULL
while	NULL
retaining	NULL
biological	NULL
(	NULL
anti-apoptotic	NULL
)	NULL
function	NULL
,	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
9575	NULL
and	NULL
we	NULL
have	NULL
initiated	NULL
those	NULL
studies	NULL
.	NULL

Also	NULL
worth	NULL
exploring	NULL
are	NULL
ways	NULL
to	NULL
upregulate	NULL
expression	NULL
of	NULL
the	NULL
endogenous	NULL
bel-2	NULL
gene	NULL
or	NULL
one	NULL
of	NULL
its	NULL
anti-apoptotic	NULL
relatives	NULL
,	NULL
preferably	NULL
selectively	NULL
in	NULL
HIV-infected	NULL
cells	NULL
.	NULL

IL-10	NULL
,	NULL
stem	NULL
cell	NULL
factor	NULL
,	NULL
and	NULL
other	NULL
cytokines	NULL
that	NULL
increase	NULL
bel-2	NULL
levels	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
,	NULL
NFB	NULL
pathway	NULL
inhibitors	NULL
such	NULL
as	NULL
pentoxifylline	NULL
and	NULL
thalidomide	NULL
,	NULL
and	NULL
a	NULL
variety	NULL
of	NULL
chemical	NULL
antioxidants	NULL
that	NULL
inhibit	NULL
HIV	NULL
and	NULL
may	NULL
reduce	NULL
cell	NULL
death	NULL
are	NULL
currently	NULL
in	NULL
early	NULL
clinical	NULL
trials	NULL
for	NULL
AIDS	NULL
(	NULL
16	NULL
,	NULL
17	NULL
,	NULL
23	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Drs	NULL
.	NULL

Stanley	NULL
Korsmeyer	NULL
(	NULL
Washington	NULL
University	NULL
,	NULL
St.	NULL
Louis	NULL
)	NULL
and	NULL
Michael	NULL
Cleary	NULL
(	NULL
Stanford	NULL
University	NULL
)	NULL
provided	NULL
cDNA	NULL
for	NULL
be/-2	NULL
.	NULL

Dr.	NULL
G.	NULL
Litwack	NULL
(	NULL
Jefferson	NULL
University	NULL
,	NULL
Philadelphia	NULL
)	NULL
donated	NULL
a	NULL
baculovirus-based	NULL
expression	NULL
system	NULL
for	NULL
bel-2	NULL
.	NULL

We	NULL
would	NULL
also	NULL
like	NULL
to	NULL
thank	NULL
Dr.	NULL
L.	NULL
Waxman	NULL
(	NULL
Merck	NULL
)	NULL
for	NULL
his	NULL
suggestions	NULL
regarding	NULL
the	NULL
purification	NULL
of	NULL
bel-2	NULL
.	NULL

D.	NULL
McCabe	NULL
,	NULL
M.	NULL
Hillman	NULL
,	NULL
and	NULL
J.	NULL
Duke	NULL
supplied	NULL
purified	NULL
HIV	NULL
protease	NULL
.	NULL

Viral	NULL
assays	NULL
were	NULL
carried	NULL
out	NULL
by	NULL
C.	NULL
Reid	NULL
and	NULL
S.	NULL
Garber	NULL
.	NULL

Drs	NULL
.	NULL

M.	NULL
Lively	NULL
(	NULL
Wake	NULL
Forest	NULL
University	NULL
)	NULL
,	NULL
J.	NULL
O'Brian	NULL
,	NULL
S.	NULL
Erickson-Viitanen	NULL
,	NULL
and	NULL
H.	NULL
Rabin	NULL
offered	NULL
many	NULL
useful	NULL
suggestions	NULL
and	NULL
reagents	NULL
.	NULL

P.R.S	NULL
.	NULL

and	NULL
M.W.F	NULL
.	NULL

were	NULL
funded	NULL
by	NULL
the	NULL
DuPont	NULL
Merck	NULL
Postdoctoral	NULL
Program	NULL
.	NULL

1	NULL
.	NULL

Terai	NULL
,	NULL
C.	NULL
,	NULL
Kornbluth	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Pauza	NULL
,	NULL
C.	NULL
,	NULL
Richman	NULL
,	NULL
D.	NULL
D.	NULL
&	NULL
Carson	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

87	NULL
,	NULL
1710-1715	NULL
.	NULL

2	NULL
.	NULL

Meyaard	NULL
,	NULL
L.	NULL
,	NULL
Otto	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Jonker	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
Mijnster	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Keet	NULL
,	NULL
R.	NULL
P.	NULL
M.	NULL
&	NULL
Miedema	NULL
,	NULL
F.	NULL
(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
217-219	NULL
.	NULL

3	NULL
.	NULL

Ameisen	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
AIDS	NULL
8	NULL
,	NULL
1197-1213	NULL
.	NULL

4	NULL
.	NULL

Westendorp	NULL
,	NULL
M.	NULL
O.	NULL
,	NULL
Frank	NULL
,	NULL
R.	NULL
,	NULL
Ochsenbauer	NULL
,	NULL
C.	NULL
,	NULL
Stricker	NULL
,	NULL
K.	NULL
,	NULL
Dhein	NULL
,	NULL
J.	NULL
,	NULL
Walczak	NULL
,	NULL
H.	NULL
,	NULL
Debatin	NULL
,	NULL
K.-M.	NULL
&	NULL
Krammer	NULL
,	NULL
P.	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
375	NULL
,	NULL
497-500	NULL
.	NULL

5	NULL
.	NULL

Krausslich	NULL
,	NULL
H.-G.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
3213-3217	NULL
.	NULL

6	NULL
.	NULL

Kerr	NULL
,	NULL
J.	NULL
F.	NULL
R.	NULL
,	NULL
Wyllie	NULL
,	NULL
A.	NULL
H.	NULL
&	NULL
Currie	NULL
,	NULL
A.	NULL
R.	NULL
(	NULL
1972	NULL
)	NULL
Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
26	NULL
,	NULL
239-254	NULL
.	NULL

7	NULL
.	NULL

Memon	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Petrak	NULL
,	NULL
D.	NULL
,	NULL
Moreno	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

&	NULL
Zacharchuk	NULL
,	NULL
C.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
180	NULL
,	NULL
15-24	NULL
.	NULL

8	NULL
.	NULL

Korsmeyer	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Trends	NULL
Genet	NULL
.	NULL

11	NULL
,	NULL
101-105	NULL
.	NULL

9	NULL
.	NULL

Anderson	NULL
,	NULL
M.	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
in	NULL
Glutathione	NULL
:	NULL
Chemical	NULL
,	NULL
Biochemical	NULL
and	NULL
Medical	NULL
Aspects	NULL
,	NULL
eds	NULL
.	NULL

Dolphin	NULL
,	NULL
D.	NULL
,	NULL
Avramovic	NULL
,	NULL
O	NULL
.	NULL

&	NULL
Poulson	NULL
,	NULL
R.	NULL
(	NULL
Wiley	NULL
,	NULL
New	NULL
York	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

339-365	NULL
.	NULL

10	NULL
.	NULL

Esterbauer	NULL
,	NULL
H.	NULL
&	NULL
Cheeseman	NULL
,	NULL
K.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

186	NULL
,	NULL
407-421	NULL
.	NULL

11	NULL
.	NULL

Schreck	NULL
,	NULL
R.	NULL
,	NULL
Rieber	NULL
,	NULL
P.	NULL
&	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

10	NULL
,	NULL
2247-2258	NULL
.	NULL

12	NULL
.	NULL

Rizzo	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

&	NULL
Korant	NULL
,	NULL
B.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

241	NULL
,	NULL
16-29	NULL
.	NULL

13	NULL
.	NULL

Wolff	NULL
,	NULL
J.	NULL
,	NULL
Malone	NULL
,	NULL
R.	NULL
W.	NULL
,	NULL
Williams	NULL
,	NULL
P.	NULL
,	NULL
Chong	NULL
,	NULL
W.	NULL
,	NULL
Acsadi	NULL
,	NULL
G.	NULL
,	NULL
Jani	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Felgner	NULL
,	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
247	NULL
,	NULL
1465-1468	NULL
.	NULL

14	NULL
.	NULL

Lam	NULL
,	NULL
P.	NULL
Y.	NULL
S.	NULL
,	NULL
Jadhav	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
Eyermann	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Hodge	NULL
,	NULL
C.	NULL
N.	NULL
,	NULL
Ru	NULL
,	NULL
Y.	NULL
,	NULL
Bacheler	NULL
,	NULL
L.	NULL
T.	NULL
,	NULL
Meek	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Otto	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Rayner	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Wong	NULL
,	NULL
Y.	NULL
N.	NULL
,	NULL
Chang	NULL
,	NULL
C.-H.	NULL
,	NULL
Weber	NULL
,	NULL
P.	NULL
C.	NULL
,	NULL
Jackson	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Sharpe	NULL
,	NULL
T.	NULL
R.	NULL
&	NULL
Erickson-Viitanen	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Science	NULL
263	NULL
,	NULL
380-384	NULL
.	NULL

15	NULL
.	NULL

Freitas	NULL
,	NULL
J.	NULL
P.	NULL
&	NULL
Filipe	NULL
,	NULL
P.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Biol	NULL
.	NULL

Trace	NULL
Elem	NULL
.	NULL

Res	NULL
.	NULL

47	NULL
,	NULL
307-311	NULL
.	NULL

16	NULL
.	NULL

Biswas	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
Dezube	NULL
,	NULL
B.J	NULL
.	NULL

,	NULL
Ahlers	NULL
,	NULL
C.	NULL
M.	NULL
&	NULL
Pardee	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J	NULL
.	NULL

AIDS	NULL
6	NULL
,	NULL
778-786	NULL
.	NULL

17	NULL
.	NULL

Weissman	NULL
,	NULL
D.	NULL
,	NULL
Poli	NULL
,	NULL
G.	NULL
&	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
10	NULL
,	NULL
1199-1206	NULL
.	NULL

18	NULL
.	NULL

Tomasselli	NULL
,	NULL
A.	NULL
G.	NULL
&	NULL
Heinrikson	NULL
,	NULL
R.	NULL
L.	NULL
(	NULL
1994	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

241	NULL
,	NULL
279-301	NULL
.	NULL

19	NULL
.	NULL

De	NULL
Rossi	NULL
,	NULL
A.	NULL
,	NULL
Ometto	NULL
,	NULL
L.	NULL
,	NULL
Roncella	NULL
,	NULL
S.	NULL
,	NULL
D'Andrea	NULL
,	NULL
E.	NULL
,	NULL
Menin	NULL
,	NULL
C.	NULL
,	NULL
Calderazzo	NULL
,	NULL
F.	NULL
,	NULL
Rowe	NULL
,	NULL
M.	NULL
,	NULL
Ferrarini	NULL
,	NULL
M.	NULL
&	NULL
Chieco-Bianchi	NULL
,	NULL
L.	NULL
(	NULL
1994	NULL
)	NULL
Virology	NULL
198	NULL
,	NULL
234-244	NULL
.	NULL

20	NULL
.	NULL

Reed	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Stein	NULL
,	NULL
C.	NULL
,	NULL
Subasinghe	NULL
,	NULL
C.	NULL
,	NULL
Haldar	NULL
,	NULL
S.	NULL
,	NULL
Croce	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Yum	NULL
,	NULL
S.	NULL
&	NULL
Cohen	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

50	NULL
,	NULL
6565-6570	NULL
.	NULL

21	NULL
.	NULL

-	NULL
Nakayama	NULL
,	NULL
K.-L.	NULL
,	NULL
Nakayama	NULL
,	NULL
K.	NULL
,	NULL
Negishi	NULL
,	NULL
I.	NULL
,	NULL
Kuida	NULL
,	NULL
K.	NULL
,	NULL
Shinkai	NULL
,	NULL
Y.	NULL
,	NULL
Louie	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Fields	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
Lucas	NULL
,	NULL
P.	NULL
L.	NULL
,	NULL
Stewart	NULL
,	NULL
V.	NULL
,	NULL
Alt	NULL
,	NULL
F.	NULL
W.	NULL
&	NULL
Loh	NULL
,	NULL
D.	NULL
Y	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Science	NULL
261	NULL
,	NULL
1584-1588	NULL
.	NULL

22	NULL
.	NULL

Kane	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Sarafian	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Anton	NULL
,	NULL
R.	NULL
,	NULL
Hahn	NULL
,	NULL
H.	NULL
,	NULL
Gralla	NULL
,	NULL
E.	NULL
B.	NULL
,	NULL
Valentine	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Ord	NULL
,	NULL
T.	NULL
&	NULL
Bredesen	NULL
,	NULL
D.	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
1274-1277	NULL
.	NULL

23	NULL
.	NULL

-	NULL
Staal	NULL
,	NULL
F.	NULL
,	NULL
Roederer	NULL
,	NULL
M.	NULL
,	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

&	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
,	NULL
9943-9947	NULL
.	NULL

24	NULL
.	NULL

Antoni	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Sabbatini	NULL
,	NULL
P.	NULL
,	NULL
Rabson	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

&	NULL
White	NULL
,	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

69	NULL
,	NULL
2384-2392	NULL
.	NULL

25	NULL
.	NULL

Olsen	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
Kehren	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Dybdahl-Sissoko	NULL
,	NULL
N.	NULL
R.	NULL
&	NULL
Hinshaw	NULL
,	NULL
V.	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

70	NULL
,	NULL
663-666	NULL
.	NULL

9576	NULL
Cell	NULL
Biology	NULL
:	NULL
Strack	NULL
et	NULL
al	NULL
.	NULL

26	NULL
.	NULL

Levine	NULL
,	NULL
B.	NULL
,	NULL
Huang	NULL
,	NULL
Q.	NULL
,	NULL
Isaacs	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Reed	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Griffin	NULL
,	NULL
D.	NULL
E.	NULL
&	NULL
Hardwick	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
361	NULL
,	NULL
739-742	NULL
.	NULL

27	NULL
.	NULL

Lin	NULL
,	NULL
K.	NULL
,	NULL
Lee	NULL
,	NULL
S.	NULL
,	NULL
Nahayanan	NULL
,	NULL
R.	NULL
,	NULL
Baraban	NULL
,	NULL
J.	NULL
,	NULL
Hardwick	NULL
,	NULL
J.	NULL
M.	NULL
&	NULL
Ratan	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

131	NULL
,	NULL
1149-1161	NULL
.	NULL

28	NULL
.	NULL

-	NULL
Poorman	NULL
,	NULL
R.	NULL
,	NULL
Tomaselli	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Heinrikson	NULL
,	NULL
R.	NULL
L.	NULL
&	NULL
Kezdy	NULL
,	NULL
F.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
14554-14661	NULL
.	NULL

29	NULL
.	NULL

Subramanian	NULL
,	NULL
T.	NULL
,	NULL
Boyd	NULL
,	NULL
J.	NULL
M.	NULL
&	NULL
Chimmadurai	NULL
,	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Onco-gene	NULL
11	NULL
,	NULL
2403-2409	NULL
.	NULL

30	NULL
.	NULL

Kornbluth	NULL
,	NULL
R.	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

56	NULL
,	NULL
247-256	NULL
.	NULL

31	NULL
.	NULL

Riviere	NULL
,	NULL
Y.	NULL
,	NULL
Blank	NULL
,	NULL
V.	NULL
,	NULL
Kourilsky	NULL
,	NULL
P.	NULL
&	NULL
Isracl	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
350	NULL
,	NULL
625-626	NULL
.	NULL

32	NULL
.	NULL

Zhang	NULL
,	NULL
D.	NULL
,	NULL
Zhang	NULL
,	NULL
N.	NULL
,	NULL
Wick	NULL
,	NULL
M.	NULL
M.	NULL
&	NULL
Byrn	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
11	NULL
,	NULL
223-230	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
Korant	NULL
,	NULL
B.	NULL
D.	NULL
&	NULL
Rizzo	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Biomed	NULL
.	NULL

Biochim	NULL
.	NULL

Acta	NULL
50	NULL
,	NULL
643-646	NULL
.	NULL

Kaplan	NULL
,	NULL
A.	NULL
H.	NULL
&	NULL
Swanstrom	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
4528-4532	NULL
.	NULL

Levy	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Brouet	NULL
,	NULL
J.-C.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

93	NULL
,	NULL
424-428	NULL
.	NULL

Carson	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
Haldar	NULL
,	NULL
S.	NULL
,	NULL
Baiocchi	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Croce	NULL
,	NULL
C.	NULL
M.	NULL
&	NULL
Caligiuri	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91	NULL
,	NULL
7553-7557	NULL
.	NULL

Gougeon	NULL
,	NULL
M.-L.	NULL
&	NULL
Montagnier	NULL
,	NULL
L.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
260	NULL
,	NULL
1269-1270	NULL
.	NULL

Alnemri	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Robertson	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
Fernandes	NULL
,	NULL
T.	NULL
F.	NULL
,	NULL
Croce	NULL
,	NULL
C.	NULL
M.	NULL
&	NULL
Litwack	NULL
,	NULL
G.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
7295-7299	NULL
.	NULL

Vlasuk	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Waxman	NULL
,	NULL
L.	NULL
,	NULL
Davis	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Dixon	NULL
,	NULL
R.	NULL
A.	NULL
F.	NULL
,	NULL
Schultz	NULL
,	NULL
L.	NULL
D.	NULL
,	NULL
Hofmann	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Tung	NULL
,	NULL
J.-S.	NULL
,	NULL
Schulman	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Ellis	NULL
,	NULL
R.	NULL
W.	NULL
,	NULL
Bencen	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
Duong	NULL
,	NULL
L.	NULL
T.	NULL
&	NULL
Polokoff	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
12106-12112	NULL
.	NULL

